tradingkey.logo

Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque Psoriasis

ReutersApr 18, 2025 2:18 PM

- Akeso Inc 9926.HK:

  • AKESO: EBDAROKIMAB APPROVED IN CHINA FOR MODERATE - TO - SEVERE PLAQUE PSORIASIS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles